Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Abstract Background In patients with rheumatoid arthritis (RA), patient‐reported outcomes (PROs) may vary by disease‐modifying antirheumatic drug (DMARD) class. This study aimed to assess the impact of biological/targeted synthetic DMARDs (b/tsDMARDs) on PROs in patients with sustained low RA activi...

Descrición completa

Detalles Bibliográficos

Principais autores:	Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi Tsuchimoto, Koji Kinoshita, Itaru Matsumura
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2026-06-01
Series:	Rheumatology & Autoimmunity
Assuntos:	b/tsDMARDs methotrexate patient‐reported outcomes rheumatoid arthritis
Acceso en liña:	https://doi.org/10.1002/rai2.70048
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!